Addex Therapeutics upgraded by H.C. Wainwright with a new price target
$ADXN
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright upgraded Addex Therapeutics from Neutral to Buy and set a new price target of $30.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $30.00 | Neutral → Buy | H.C. Wainwright |
| 2/11/2022 | $28.00 → $21.00 | Buy | HC Wainwright & Co. |
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025. Tit
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025. The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a
H.C. Wainwright upgraded Addex Therapeutics from Neutral to Buy and set a new price target of $30.00
HC Wainwright & Co. reiterated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $21.00 from $28.00 previously
HC Wainwright & Co. initiated coverage of Addex Therapeutics with a rating of Buy and set a new price target of $28.00
Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutic
Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025. Tit
Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
SC 13D/A - Addex Therapeutics Ltd. (0001574232) (Subject)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025. The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a
Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. "It's great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex